Caris Molecular Tumor Board

The Caris Molecular Tumor Board provides oncologists with the opportunity to interact with leading cancer experts from across the country to obtain interpretation of molecular findings and therapeutic guidance for individual patients.

Collaborative Cancer Treatment

The Caris Molecular Tumor Board (CMTB), provides oncologists with the opportunity to interact with leading cancer experts from across the country to obtain interpretation of molecular findings and therapeutic guidance for individual patients. This proprietary virtual tumor board platform is an innovative, real-time approach to deciphering complex data and treatment decisions on difficult-to-treat cases. The efficient access to cutting-edge information provided by the Caris Molecular Tumor Board allows oncologists to focus their efforts on what matters most – developing the most informed personalized treatment strategies for their patients.

CMTB Platform

Our platform facilitates asynchronous discussions to collaborate more efficiently on patient cases while providing:

  • Collaboration – Specialists from different institutions working together to ensure the appropriate diagnostic tests and treatment options are being considered for your patients
  • Expert Review & Interpretation – Streamlined process allows each patient case submitted to be personally evaluated and discussed by members of the Caris Molecular Tumor Board
  • Broad Review of Treatment Options – Reviews beyond the standard of care therapies, with recommendations that could include FDA-approved treatments, clinical trials of matched targeted therapies, and additional tumor or germline genetic testing options
  • Accelerated Review Time – Each patient case submitted is typically reviewed within 7 days, with a physician signed report summary released following case conclusion
  • Virtual Platform – Allows oncologists to post and review patient medical records and other patient data from different parts of the country while allowing their patients to be treated within their own community

Submit a case for review

To submit a case for review, register for an account on the CMTB portal and select “Submit New Case.”

Caris Molecular Tumor Board Case Studies

The CMTB works one on one with oncologists to obtain interpretation of molecular findings and therapeutic guidance on difficult-to-treat cases. Read how the CMTB approached patients diagnosed with cancer.

Cecal cancer with liver and mesenteric metastases


  • 79-year-old female
  • Diagnosed with stage IV cecal cancer with liver and mesenteric metastases
  • Patient received 2 weeks of chemotherapy (capecitabine) prior to Caris testing
  • Caris testing identified the tumor carries two highly actionable alterations

TNBC tumors tested by DNA and RNA sequencing


  • 61-year-old female
  • Originally diagnosed with localized triple-negative breast cancer (TNBC) in 2001
  • Over the 20 years since the initial diagnosis, developed suspected de novo breast cancers and numerous metastases
  • Went on various clinical trials and recently enrolled in the All4Cure research study 

Metastatic extrahepatic bile duct cancer 


  • 57-year-old female 
  • Diagnosed with metastatic extrahepatic bile duct cancer with a proven liver metastasis
  • Family history of breast cancer
  • Father has a known pathogenic variant of PALB2 gene

Malignant peripheral nerve sheath tumor 


  • 32-year-old male
  • Former smoker with inherited neurofibromatosis 1 (NF1) syndrome
  • Previously undergone multiple resections for neurofibromas.
  • Progressive pain in the distal right thigh with imaging suspicious of a malignant peripheral nerve sheath tumor (MPNST)

Neuroendocrine pancreatic cancer 


  • 24-year-old female patient, 6 months post-partum.
  • Family history of pancreatic cancer (maternal grandfather) and breast cancer (two maternal great aunts), but mother’s germline testing was negative for pathogenic BRCA1/2 mutations.
  • Presented with abdominal pain to the ER where imaging revealed asymmetric breast size, suggestive of multifocal breast cancer, and multiple liver masses.
  • Subsequent imaging revealed a hypodense mass along the pancreatic head, ascites in the abdomen and pelvis, and trace bilateral pleural effusions. 

Metastatic recurrent pancreatic adenocarcinoma 


  • 65-year-old male patient.
  • Presented with weight loss and jaundice and diagnosed with pancreatic adenocarcinoma.
  • Underwent a Whipple procedure and completed adjuvant FOLFIRINOX.
  • Restaging scans showed no evidence of disease (NED) for 18 months. At 21 months, local recurrence was detected and treated with Xeloda and radiation.
  • Six months after chemotherapy and radiation, distant lymphadenopathy and new lung nodules were observed. 

Metastatic NUT carcinoma  


  • A 36-year-old female patient presented with shortness of breath and chest pain and underwent tumor and stent placement.
  • Pathology showed poorly differentiated carcinoma with squamous and undifferentiated components.
  • A brain MRI showed foci of cortical enhancement in both right parietal and left occipital lobes, concerning for metastatic disease.
  • Additional imaging revealed a lytic lesion within the superior endplate of the T2 vertebral body, concerning for a focus of osseus metastasis.
  • Prior to initiating treatment, tumor was staged as T4 N3 M1c, Stage IVB

Expert Board Members

Our panel of experts come from many of the leading cancer institutions in the world today to review every case and provide individualized diagnostic and therapeutic evaluations for each patient.


If you have questions about Caris molecular profiling please contact us today.